Enzyme replacement and enhancement therapies for lysosomal diseases

Journal of Inherited Metabolic Disease

Volumn 27, Issue 3, 2004, Pages 385-410

  Desnick, R J ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ADENOSINE DEAMINASE; AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA 1 ANTITRYPSIN; ALPHA GALACTOSIDASE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHAPERONE; DEOXYGALACTONOJIRIMYCIN; DEOXYRIBONUCLEASE; DIMETHYL SULFOXIDE; GALACTOSE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; GLYCEROL; GROWTH HORMONE; IDURONATE 2 SULFATASE; LARONIDASE; LEVO IDURONIDASE; MUTANT PROTEIN; N ACETYLGALACTOSAMINE 4 SULFATASE; N OCTYL 4 EPI BETA VALIENAMINE; OPIATE; PANCREAS ENZYME; PLACEBO; RECEPTOR BLOCKING AGENT; RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG PENETRATION; DRUG SAFETY; ENZYME REPLACEMENT; ENZYME STABILITY; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEADACHE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; NIEMANN PICK DISEASE; NONHUMAN; PROTEIN FOLDING; PROTEIN FUNCTION; RASH; REVIEW; SIDE EFFECT; URTICARIA;

ENZYMES; HUMANS; LYSOSOMAL STORAGE DISEASES; RECOMBINANT PROTEINS;

EID: 2942588994     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BOLI.0000031101.12838.c6     Document Type: Review

References (114)

1. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278: 40911-40916.
2. Amaifitano A, Bengur AR, Morse RP, et al (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132-138.
3. Amaral MD (2004) CFTR and chaperones. J Mol Neurosci 23: 41-48.
4. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding disease. Nature 426: 905-909.
5. Asano N, Ishii S, Kizu H, et al (2000) In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267: 4179-4186.
6. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87: 1913-1916.
7. Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470.
8. Beck M, Wraith JE, Clarke AA, et al (2002) A phase 3 study of rhIDUA enzyme therapy for MPS I. J Inherit Metab Dis 25: 120.
9. Bijvoet AG, Van Hirtum H, Kroos MA, et al (1999) Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8: 2145-2153.
10. Bonten EJ, Toy JN, Mann L, et al (2002) Effective enzyme replacement therapy of murine galactosialidosis using insect cell-expressed PPCA and neuraminidase. Am J Hum Genet 71: 420.
11. Brady RO, Barton NW (1991) Enzyme replacement therapy for type 1 Gaucher disease. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 153-168.
12. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 291: 989-993.
13. Brady RO, Barranger JA, Gal AE, Pentchev PG, Furbish FS (1980) Status of enzyme replacement therapy for Gaucher disease. In Desnick RJ, ed. Enzyme Therapy in Genetic Disease: 2. New York: Alan R. Liss, 361-368.
14. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ (1996) Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1: 117-125.
15. 1-AT deficiency. Proc Natl Acad Sci USA 97: 1796-1801.
16. Byers S, Crawley AC, Brumfield LK, Nuttall JD, Hopwood JJ (2000) Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr Res 47: 743-749.
17. Cabral CM, Liu Y, Sifers RN (2001) Dissecting glycoprotein quality control in the secretory pathway. Trends Biochem Sci 26: 619-624.
18. Cantz M, Kresse H (1974) Sandhoff disease: defective glycosaminoglycan catabolism in cultured fibroblasts and its correction by β-N-acetylhexosaminidase. Eur J Biochem 47: 581-590.
19. 1-Antitrypsin deficiency - a model for conformational diseases. N Engl J Med 346: 45-53.
20. Clarke LA, Wraith JE, Beck M, et al (2003) Aldurazyme (iduronidase) enzyme replacement therapy for MPS I: 48-week extension data. Am J Hum Genet 73: 623.
21. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding disease. Nature 426: 905-909.
22. de Duve C (1964) From cytases to lysosomes. Fed Proc 23: 1045.
23. De Schoenmakere G, Chauveau D, Grunfeld JP (2003) Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18: 33-35.
24. Desnick RJ (ed.) (1980) Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss.
25. Desnick RJ (1991) Treatment of Genetic Diseases. New York: Churchill Livingstone.
26. Desnick RJ, Bernlohr RW, Krivit W, eds (1973) Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series. New York: The National Foundation.
27. Desnick RJ, Thorpe SR, Fiddler MB (1976) Toward enzyme therapy for lysosomal storage diseases. Physiol Rev 56: 57-99.
28. Desnic, RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn.; New York: McGraw-Hill, 3733-3774.
29. Desnick RJ, Brady R, Barranger J, et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338-346.
30. Dobrenis K, Joseph A, Rattazzi MC (1992) Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. Proc Natl Acad Sci USA 89: 2297-2301.
31. Doebber TW, Wu MS, Bugianesi RL, et al (1982) Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase. J Biol Chem 257: 2193-2199.
32. Du H, Schiavi S, Levine M, et al (2001) Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet 10: 1639-1648.
33. Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 286: 1882-1888.
34. Eng CM, Banikazemi M, Gordon R, et al (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722.
35. Eng CM, Guffon N, Wilcox WR, et al (2001b) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9-16.
36. Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Medicine 5: 112-115.
37. Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24: 355-360.
38. Fewell SW, Travers KJ, Weissman JS, Brodsky JL (2001) The action of molecular chaperones in the early secretory pathway. Annu Rev Genet 35: 149-191.
39. Fleischer LD, Gaull GE (1980) Enzyme manipulation by specific megavitamin therapy. In Desnick RJ, ed. Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss, 239-268.
40. Frustaci A, Chimenti C, Ricci R, et al (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345: 25-32.
41. Furbish FS, Steer CJ, Kreet NL, Barranger JA (1981) Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 673: 425-434.
42. Gelman MS, Kopito RR (2002) Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J Clin Invest 110: 1591-1597.
43. Ghosh P, Dahms NM, Kornfeld S (2003) Mannose-6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4: 202-212.
44. Grabowski GA, Barton NW, Pastores G, et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33-39.
45. Grabowski GA, Leslie N, Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 12: 115-133.
46. Guffon N, Fouilhoux A (2004) Clinical benefit in Fabry patients given enzyme replacement therapy - a case series. J Inherit Metab Dis, in press.
47. Harmatz P, Whitley CB, Waber L, et al (2002) A Phase I/II study of enzyme replacement therapy (ERT) for mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome): 48 week progress report. Am J Hum Genet 71: 582.
48. Harmatz P, Ketteridge D, Steiner R, et al (2003) A phase II open-label clinical study of efficacy and safety of recominant human N-acetylgalactosamine 4-sulfatase (rhASB) enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy sydrome). Am J Hum Genet 73: 623.
49. Harmatz P, Whitley CB, Waber L, et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144: 574-580.
50. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288-1292.
51. Ioannou YA, Bishop DF, Desnick RJ (1992) Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol 119: 1137-1150.
52. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ (2001) Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68: 14-25.
53. Johnson WG, Desnick RJ, Long DM, et al (1973) Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. In Desnick RJ, Bernlohr RW, Krivit W, eds. Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series. New York: The National Foundation, 120-124.
54. Kakkis ED, McEntee MF, Schmidtchen A, et al (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156-167.
55. Kakkis E, Muenzer J, Tiller G, et al (1998) Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis I: results of a human clinical trial. Am J Hum Genet 63 (supplement): A25.
56. Kakkis ED, Muenzer J, Tiller GE, et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188.
57. Kikuchi T, Yang HW, Pennybacker M, et al (1998) Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101: 827-833.
58. Kishnani P, Voit T, Nicolino M, et al (2002) Treatment of classical infantile Pompe disease (CIPD) with recombinant human acid α-glucosidase (rhGAA): preliminary 6 month data from a Phase 2 study. Am J Hum Genet 71: 582.
59. Kornfeld S (1990) Lysosomal enzyme targeting. Biochem Soc Trans 18: 367-374.
60. Lee K, Jin X, Zhang K, et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13: 305-313.
61. Linthorst GE, Blom D, Specijer D, Hollak CEM, Awrts JMFG (2002) Therapy for Fabry disease; comparison of agalsidase alpha and beta enzyme preparations. J Inherit Metab Dis 25: A115.
62. Loo TW, Clarke DM (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272: 709-712.
63. Matsuda J, Suzuki O, Oshima A, et al (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci USA 100: 15912-15917.
64. Miranda SR, He X, Simonaro CM, et al (2000) Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J 14: 1988-1995.
65. Molinari M, Calanca V, Galli C, Lucca P, Paganetti P (2003) Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science 299: 1397-1400.
66. Morello JP, Petaja-Repo UE, Bichet DG, Bouvier M (2000a) Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci 21: 466-469.
67. 2 vasopressin receptor mutants. J Clin Invest 105: 887-895.
68. Muenzer J, Towle D, Calikoglu M, McCandlless S (2002) A Phase I/II clinical study evaluating the safety and clinical activity of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Am J Hum Genet 71: 582.
69. Muenzer J, Calikoglu M, Towle D, McCandlless S, Kimura A (2003) The one year experience of enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome). Am J Hum Genet 73: 623.
70. Nakao S, Takenaka, T, Maeda M, et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333: 288-293.
71. O'Brien JS, Miller AL, Loverde AW, Veath ML (1973) Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science 181: 753-755.
72. Oda Y, Hosokawa N, Wada I, Nagata K (2003) EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299: 1394-1397.
73. Okumiya T, Ishii S, Takenaka T, et al (1995) Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun 214: 1219-1224.
74. Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408-416.
75. Petaja-Repo UE, Hogue M, Bhalla S, et al (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J 21: 1628-1637.
76. Porter MT, Fluharty AL, Kihara H (1971) Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 172: 1263-1265.
77. Powell K, Zeitlin PL (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev 54: 1395-1408.
78. Princiotta ME, Finzi D, Qian SB, et al (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18: 343-354.
79. Rattazzi MC, Dobrenis K (1991) Enzyme replacement: overview and prospects. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 131-152.
80. Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82: 1402-1409.
81. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93: 2081-2088.
82. Rubenstein RC, Egan ME, Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing deltaF508-CFTR. J Clin Invest 100: 2457-2465.
83. Sabatini DD, Adesnik MB (2001) The biogenesis of membranes and organelles. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 475-484.
84. Sands MS, Vogler CA, Ohlemiller KK, et al (2001) Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 276: 43160-43165.
85. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271: 635-638.
86. Sawkar AR, Cheng WC, Beutler F, et al (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99: 15428-15433.
87. Schiffmann R, Murray GJ, Treco D, et al (2000) Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97: 365-370.
88. Schiffmann R, Kopp JB, Austin HA 3rd, et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749.
89. Schubert U, Anton LC, Gibbs J, et al (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
90. Shull RM, Kakkis ED, McEntee ME, et al (1994) Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 91: 12937-12941.
91. Tager JM, Hooghvinkel GJM, Daems WT (1974) Enzyme Therapy in Lysosomal Storage Diseases. Amsterdam: North-Holland.
92. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296: 1991-1995.
93. Treacy EP, Valle D, Scriver CR (2001) Treatment of genetic disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 175-191.
94. Tropak MB, Reid SP, Guiral M, et al (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J Biol Chem 279: 13478-13487.
95. Van den Hout H, Reuser A, Vulto A, et al (2000a) First clinical test with recombinant human α-glucosidase from rabbit milk shows therapeutic effect in Pompe disease. Am J Hum Genet 67(supplement 2): 6.
96. Van den Hout H, Reuser AJ, Vulto AG, et al (2000b) Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 356: 397-398.
97. Van den Hout JM, Reuser AJ, de Klerk JB, et al (2001) Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 24: 266-274.
98. Van den Hout JM, Kamphoven JH, Winkel LP, et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: 448-457.
99. van der Ploeg AT, Winkel LPF, van Diggelen OP, et al (2002) Preliminary findings in patients with late onset Pompe's disease treated with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 25: 118.
100. Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT (1996) High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci USA 93: 65-70.
101. Vogler C, Levy B, Galvin NJ, et al (1999) Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 45: 342-348.
102. von Scheidt W, Eng CM, Fitzmaurice TF, et al (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324: 395-399.
103. von Specht BU, Geiger B, Arnon R, et al (1979) Enzyme replacement in Tay-Sachs disease. Neurology 29: 848-854.
104. Waldek S (2003) PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 348: 1186-1187.
105. Weidemann F, Breunig F, Beer M, et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108: 1299-1301.
106. Weinreb NJ, Charrow J, Andersson HC, et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
107. Welch WJ, Brown CR (1996) Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1: 109-115.
108. Welch WJ, Howard M (2000) Antagonists to the rescue. J Clin Invest 105: 853-854.
109. Wilcox WR, Banikazemi M, Guffon N, et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet, in press.
110. Winkel LP, Van den Hout JM, Kamphoven JH, et al (2004) Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55: 495-502.
111. Wraith JE, Clarke LA, Beck M, et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (Laronidase). J Pediatr 144: 581-588.
112. 1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci USA 100: 8229-8234.
113. Yewdell JW (2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11: 294-297.
114. Young E, Chatterton C, Vellodi A, Winchester B (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis 20: 595-602.